
1. Immunology. 2021 Nov 14. doi: 10.1111/imm.13432. [Epub ahead of print]

Identifying SARS-CoV-2 'memory' NK cells from COVID-19 convalescent donors for
adoptive cell therapy.

Herrera L(1)(2), Martin-Inaraja M(1)(2), Santos S(1)(2), Inglés-Ferrándiz
M(1)(2), Azkarate A(1)(2), Perez-Vaquero MA(1)(2), Vesga MA(1)(2), Vicario JL(3),
Soria B(4)(5), Solano C(6)(7), De Paz R(8), Marcos A(8), Ferreras C(9),
Perez-Martinez A(9)(10)(11), Eguizabal C(1)(2).

Author information: 
(1)Research Unit, Basque Center for Blood Transfusion and Human Tissues,
Osakidetza, Galdakao, Spain.
(2)Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research 
Institute, Barakaldo, Spain.
(3)Histocompatibility, Centro de Transfusión de Madrid, Madrid, Spain.
(4)Instituto de Bioingeniería, Universidad Miguel Hernández de Elche, Alicante,
Spain.
(5)Instituto de Investigación Sanitaria Hospital General y Universitario de
Alicante (ISABIAL), Alicante, Spain.
(6)Hospital Clínico Universitario de Valencia/Instituto de Investigación
Sanitaria INCLIVA, Valencia, Spain.
(7)School of Medicine, University of Valencia, Spain.
(8)Hematology Department, University Hospital La Paz, Madrid, Spain.
(9)Hospital La Paz Institute for Health Research, IdiPAZ, University Hospital La 
Paz, Madrid, Spain.
(10)Pediatric Hemato-Oncology Department, University Hospital La Paz, Madrid,
Spain.
(11)Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.

COVID-19 disease is the manifestation of syndrome coronavirus 2 (SARS-CoV-2)
infection, which is causing a worldwide pandemic. This disease can lead to
multiple and different symptoms, being lymphopenia associated with severity one
of the most persistent. Natural killer cells (NK cells) are part of the innate
immune system, being fighting against virus-infected cells one of their key
roles. In this study, we determined the phenotype of NK cells after COVID-19 and 
the main characteristic of SARS-CoV-2-specific-like NK population in the blood of
convalescent donors. CD57+ NKG2C+ phenotype in SARS-CoV-2 convalescent donors
indicates the presence of 'memory'/activated NK cells as it has been shown for
cytomegalovirus infections. Although the existence of this population is donor
dependent, its expression may be crucial for the specific response against
SARS-CoV-2, so that, it gives us a tool for selecting the best donors to produce 
off-the-shelf living drug for cell therapy to treat COVID-19 patients under the
RELEASE clinical trial (NCT04578210).

© 2021 The Authors. Immunology published by John Wiley & Sons Ltd.

DOI: 10.1111/imm.13432 
PMID: 34775592 

